Navigation Links
BYDUREON™ RECEIVES MARKETING AUTHORIZATION IN EUROPE
Date:6/21/2011

digesting food. Antibodies may develop with use of BYETTA. Patients who develop high titers to exenatide could have worsening or failure to achieve adequate glycemic control. Consider alternative therapy if this occurs. Severe allergic reactions can happen with BYETTA. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug.

The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For additional important safety information about BYETTA, please see the full Prescribing Information (www.byetta.com/pi) and Medication Guide (www.byetta.com/mg).

About Amylin, Lilly and Alkermes

Amylin and Lilly partnered to develop and market BYDUREON, which is based on proprietary technology for long-acting medications developed by Alkermes, Inc. BYDUREON was approved in the EU in June 2011 and is under regulatory review in the U.S.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has b
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BYDUREON™ Recommended for Approval in Europe
2. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
3. BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010
4. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
5. Omnicells OmniRx Automated Medication Dispensing System Receives 2011 Best in KLAS Award
6. EndoSphere Inc. Receives Patent for Obesity Treatment
7. Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease
8. TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval
9. Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients
10. Mindray Medical Receives the 2011 Medical Device Excellence Award for its V Series Patient Monitoring System
11. MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards ... been published for use on the CDISC website . These three Therapeutic ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , CHICAGO, Nov. 24 The holiday season can be ... But for many people, especially those recovering from an eating ... failures and anxiety about an uncertain future. Family gatherings with ... be challenging and sometimes awkward. , "In my ...
... , , FLINT, Mich., Nov. 24 ... insurance plans designed specifically for individuals 18 to 64 ... coverage directly. , The new HealthPlus Signature ... agents and brokers throughout the HealthPlus service area. More information, ...
... ... but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, ... that may identify a causative mutation for Crohn’s disease. , ... New York, NY (Vocus) November 24, 2009 ...
... , PITTSBURGH, Nov. 24 While the ... this time of the year can be difficult for those ... every day is difficult for children and families. The holiday ... , The Highmark Caring Place, A Center for Grieving Children, ...
... Ala., Nov. 24 HealthSouth Corporation (NYSE: HLS ) ... Lynch 2009 Credit Conference in New York on Dec. 2-3, 2009. ... be speaking on Thursday, Dec. 3, 2009, at 3:40 p.m. ET. ... http://investor.healthsouth.com by clicking on an available link. , ...
... rates didn,t differ greatly between high- and low-volume centers, ... Do hospitals that conduct the most angioplasties necessarily produce ... research had suggested that "practice makes perfect" when it ... over 30,000 patients finds low- and high-volume hospitals performing ...
Cached Medicine News:Health News:When Holiday Meals Aren't a Gift 2Health News:When Holiday Meals Aren't a Gift 3Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 2Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3
Extended angled sharp electrode - 1/box....
... 200, the state of the art in ... Zeiss optics with,the wide range of ICS ... as well as with an unusual scope ... stability and unique ergonomically designed. And Axiovert ...
... the way it implements the confocal principle, ... system is unmatched. It allows multi fluorescence ... and efficiency. Unprecedented flexibility for individual applications. ... guarantee fast and efficient structural and functional ...
... are the hallmark of these stereozoom fluorescent ... The top (incident) circular 9W fluorescent ring ... remaining cool to the touch. Binocular and ... to 44x zoom magnification or high-power 20x ...
Medicine Products: